Phase 2/3 Study of ALK-001 in Geographic Atrophy
Public ClinicalTrials.gov record NCT03845582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration
Study identification
- NCT ID
- NCT03845582
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Industry
- Enrollment
- 200 participants
Conditions and interventions
Interventions
- ALK-001 oral capsule Drug
- Placebo oral capsule Drug
Drug
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 6, 2019
- Primary completion
- Jul 24, 2023
- Completion
- Jun 29, 2024
- Last update posted
- Nov 2, 2025
2019 – 2024
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkeus Site | Phoenix | Arizona | 85053 | — |
| Alkeus Site | Beverly Hills | California | 90211 | — |
| Alkeus Site | Lakewood | Colorado | 80228 | — |
| Alkeus Site | Clearwater | Florida | 33761 | — |
| Alkeus Site | Fort Myers | Florida | 33912 | — |
| Alkeus Site | Gainesville | Florida | 32601 | — |
| Alkeus Site | Tampa | Florida | 33609 | — |
| Alkeus Site | Winter Haven | Florida | 33880 | — |
| Alkeus Site | Bloomington | Illinois | 61704 | — |
| Alkeus Site | Lexington | Kentucky | 40509 | — |
| Alkeus Site | Chevy Chase | Maryland | 20815 | — |
| Alkeus Site | Worcester | Massachusetts | 01605 | — |
| Alkeus Site | Grand Rapids | Michigan | 49546 | — |
| Alkeus Site | Edina | Minnesota | 55435 | — |
| Alkeus Site | Northfield | New Jersey | 08225 | — |
| Alkeus Site | Great Neck | New York | 11021 | — |
| Alkeus Site | Hauppauge | New York | 11788 | — |
| Alkeus Site | Cleveland | Ohio | 44122 | — |
| Alkeus Site | Ashland | Oregon | 97520 | — |
| Alkeus Site | Houston | Texas | 77025 | — |
| Alkeus Site-1 | San Antonio | Texas | 78240 | — |
| Alkeus Site-2 | San Antonio | Texas | 78240 | — |
| Alkeus Site | Fairfax | Virginia | 22031 | — |
| Alkeus Site | Silverdale | Washington | 98383 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03845582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2025 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03845582 live on ClinicalTrials.gov.